我喜歡做的是使用輪子期權策略慢慢進入我喜歡的交易。賣出少量有現金擔保的看跌期權,直到分配為止,然後將其翻轉成一種扼殺,在那裏我賣出針對我被分配的股票的備兑看跌期權,同時也賣出更多有現金擔保的看跌期權,以更好地利用我自己來對抗兩種方式的市場方向。例如,隨着俄羅斯和烏克蘭之間持續的衝突,我相信油價將隨着低點的持續而繼續上漲。
已翻譯
1
2
$Dare Bioscience (DARE.US)$ Looking good for re-entry tomorrow PM. Would like it to hold 1.99 at its lowest otherwise a bigger dip may come.
1
$CymaBay Therapeutics (CBAY.US)$
Holding some good support at this area long term. Spike in volume and price on 12/17. Has enough cash for approx 34 months after offering of $4/share which closed on the 11/22 I believe. Expecting Phase 2a data for short term still this year with time running out for MBX-2982 drug for Type 1 diabetes. Still undergoing enrollment on their main drug Seladelpar which is used for autoimmune liver disease with great outlook.
Institutional Holdings are around 60%ish+ according to Yahoo Finance/Ortex/and Finviz while Benzinga Pro reports Institutional Holdings at around 22%
Just back 11/11 Raymond James Maintained Strong Buy and raised PT to $14 with the average analyst PT at $11 where all are at Buy+
And a recent SC13G reported TCG Crossover Management having a 7% stake
Furthermore, according to their last earnings call, they will have sufficient funds to continue current operations into 2023 with no mentions of further dilution.
Holding some good support at this area long term. Spike in volume and price on 12/17. Has enough cash for approx 34 months after offering of $4/share which closed on the 11/22 I believe. Expecting Phase 2a data for short term still this year with time running out for MBX-2982 drug for Type 1 diabetes. Still undergoing enrollment on their main drug Seladelpar which is used for autoimmune liver disease with great outlook.
Institutional Holdings are around 60%ish+ according to Yahoo Finance/Ortex/and Finviz while Benzinga Pro reports Institutional Holdings at around 22%
Just back 11/11 Raymond James Maintained Strong Buy and raised PT to $14 with the average analyst PT at $11 where all are at Buy+
And a recent SC13G reported TCG Crossover Management having a 7% stake
Furthermore, according to their last earnings call, they will have sufficient funds to continue current operations into 2023 with no mentions of further dilution.
+6
2
$Venus Concept (VERO.US)$ Picking this up here :)
$駭維金屬加工 (HIHO.US)$ Picked this up here. PT1: 4.5; PT2: 5.07